相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome
Lauren K. Schwartz et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2016)
Inflammasome Activation Is Reactive Oxygen Species Dependent and Mediates Irinotecan-Induced Mucositis through IL-1β and IL-18 in Mice
Raquel D. N. Arifa et al.
AMERICAN JOURNAL OF PATHOLOGY (2014)
MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy
Rajesh V. Lalla et al.
CANCER (2014)
Irinotecan disrupts tight junction proteins within the gut Implications for chemotherapy-induced gut toxicity
Hannah R. Wardill et al.
CANCER BIOLOGY & THERAPY (2014)
The Intestinal Epithelial Insulin-Like Growth Factor-1 Receptor Links Glucagon-Like Peptide-2 Action to Gut Barrier Function
Charlotte X. Dong et al.
ENDOCRINOLOGY (2014)
Disruption of ZO-1/claudin-4 interaction in relation to inflammatory responses in methotrexate-induced intestinal mucositis
Kazuma Hamada et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Systematic review of agents for the management of gastrointestinal mucositis in cancer patients
Rachel J. Gibson et al.
SUPPORTIVE CARE IN CANCER (2013)
Glucagon-like peptide 2 induces vasoactive intestinal polypeptide expression in enteric neurons via phophatidylinositol 3-kinase-γ signaling
Elaine de Heuvel et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2012)
Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation
Roberto Cesar P. Lima-Junior et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine
Hannelouise Kissow et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Disruption of the Murine Glp2r Impairs Paneth Cell Function and Increases Susceptibility to Small Bowel Enteritis
Seung-Jun Lee et al.
ENDOCRINOLOGY (2012)
Severity of doxorubicin-induced small intestinal mucositis is regulated by the TLR-2 and TLR-9 pathways
Agnieszka Kaczmarek et al.
JOURNAL OF PATHOLOGY (2012)
Irinotecan Injures Tight Junction and Causes Bacterial Translocation in Rat
Toshihiro Nakao et al.
JOURNAL OF SURGICAL RESEARCH (2012)
Irinotecan (CPT-11) Chemotherapy Alters Intestinal Microbiota in Tumour Bearing Rats
Xiaoxi B. Lin et al.
PLOS ONE (2012)
GLP2-2G-XTEN: A Pharmaceutical Protein with Improved Serum Half-Life and Efficacy in a Rat Crohn's Disease Model
Susan E. Alters et al.
PLOS ONE (2012)
Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome
Palle Bekker Jeppesen
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2012)
Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome
P. B. Jeppesen et al.
GUT (2011)
Caspase-1-induced pyroptotic cell death
Edward A. Miao et al.
IMMUNOLOGICAL REVIEWS (2011)
Regulation of Tight Junction Permeability by Intestinal Bacteria and Dietary Components
Dulantha Ulluwishewa et al.
JOURNAL OF NUTRITION (2011)
The role of glucagon-like peptide-2 on apoptosis, cell proliferation, and oxidant-antioxidant system at a mouse model of intestinal injury induced by tumor necrosis factor-alpha/actinomycin D
Pelin Arda-Pirincci et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2011)
Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer
B. Glimelius et al.
PHARMACOGENOMICS JOURNAL (2011)
Does glucagon like peptide-2 receptor expression have any effect on the development of human colorectal cancer?
Goksel Bengi et al.
TURKISH JOURNAL OF GASTROENTEROLOGY (2011)
The Intestinotrophic Peptide, GLP-2, Counteracts the Gastrointestinal Atrophy in Mice Induced by the Epidermal Growth Factor Receptor Inhibitor, Erlotinib, and Cisplatin
Andreas Rosen Rasmussen et al.
DIGESTIVE DISEASES AND SCIENCES (2010)
Teduglutide, a Novel Mucosally Active Analog of Glucagon-Like Peptide-2 (GLP-2) for the Treatment of Moderate to Severe Crohn's Disease
Alan L. Buchman et al.
INFLAMMATORY BOWEL DISEASES (2010)
The Four-Herb Chinese Medicine PHY906 Reduces Chemotherapy-Induced Gastrointestinal Toxicity
Wing Lam et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Kinetics and regional specificity of irinotecan-induced gene expression in the gastrointestinal tract
Joanne M. Bowen et al.
TOXICOLOGY (2010)
The Role of Intestinal Microbiota in the Development and Severity of Chemotherapy-Induced Mucositis
Michel J. van Vliet et al.
PLOS PATHOGENS (2010)
Irinotecan-induced mucositis is associated with changes in intestinal mucins
Andrea M. Stringer et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Chemotherapy-Induced Modifications to Gastrointestinal Microflora: Evidence and Implications of Change
Andrea M. Stringer et al.
CURRENT DRUG METABOLISM (2009)
Carcinogenic Effects of Exogenous and Endogenous Glucagon-Like Peptide-2 in Azoxymethane-Treated Mice
Roman Iakoubov et al.
ENDOCRINOLOGY (2009)
Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability
P. D. Cani et al.
GUT (2009)
Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile
Andrea M. Stringer et al.
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY (2009)
UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan
Robert Ferraldeschi et al.
PHARMACOGENOMICS (2009)
Faecal microflora and β-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats
Andrea M. Stringer et al.
CANCER BIOLOGY & THERAPY (2008)
Glucagon-like peptide-2 activates beta-catenin signaling in the mouse intestinal crypt: Role of insulin-like growth factor-I
Philip E. Dube et al.
ENDOCRINOLOGY (2008)
Life in the crypt: A role for glucagon-like peptide-2?
Katherine J. Rowland et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2008)
Activated charcoal to prevent irinotecan-induced diarrhea in children
Gallegos-Castorena Sergio et al.
PEDIATRIC BLOOD & CANCER (2008)
Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis
Richard M. Logan et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Glucagon-like peptide-2 improves both acute and late experimental radiation enteritis in the rat
Sandra Torres et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
MEK activation suppresses CPT11-Induced apoptosis in rat intestinal epithelial cells through a COX-2-Dependent mechanism
Youhei Horikawa et al.
DIGESTIVE DISEASES AND SCIENCES (2007)
The intestinotrophic peptide, GLP-2, counteracts intestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, gefitinib
Kristine Juul Hare et al.
CLINICAL CANCER RESEARCH (2007)
Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2
David L. Sigalet et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2007)
Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: Analysis of phase 3 trial results
Linda S. Elting et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Irinotecan changes gene expression in the small intestine of the rat with breast cancer
Joanne M. Bowen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Establishment of a single-dose irinotecan model of gastrointestinal mucositis
Rachel J. Gibson et al.
CHEMOTHERAPY (2007)
Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea
K. Takasuna et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice
Philip E. Dube et al.
GASTROENTEROLOGY (2006)
A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer
PJ Tobin et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans
JJ Meier et al.
GASTROENTEROLOGY (2006)
GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow
XF Guan et al.
GASTROENTEROLOGY (2006)
Mammalian G proteins and their cell type specific functions
N Wettschureck et al.
PHYSIOLOGICAL REVIEWS (2005)
Proglucagon-derived peptides: Mechanisms of action and therapeutic potential
EM Sinclair et al.
PHYSIOLOGY (2005)
Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients
PB Jeppesen et al.
GUT (2005)
The glucagon-like peptide-2 receptor C terminus modulates β-arrestin-2 association but is dispensable for ligand-induced desensitization, endocytosis, and G-protein-dependent effector activation
JL Estall et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins
SN Willis et al.
GENES & DEVELOPMENT (2005)
Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans
JM Bowen et al.
PATHOLOGY (2005)
The HeLa cell glucagon-like peptide-2 receptor is coupled to regulation of apoptosis and ERK1/2 activation through divergent signaling pathways
JA Koehler et al.
MOLECULAR ENDOCRINOLOGY (2005)
GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors
C Orskov et al.
REGULATORY PEPTIDES (2005)
Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer
M Karthaus et al.
ONCOLOGY (2005)
Novel agents that potentially inhibit irinotecan-induced diarrhea
XX Yang et al.
CURRENT MEDICINAL CHEMISTRY (2005)
Mitogen-activated protein kinases in apoptosis regulation
T Wada et al.
ONCOGENE (2004)
The combination of metformin and a dipeptidyl peptidase IV inhibitor prevents 5-fluorouracil-induced reduction of small intestine weight
K Yamazaki et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2004)
Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice
J Thulesen et al.
GUT (2004)
The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer
B Nachmias et al.
SEMINARS IN CANCER BIOLOGY (2004)
Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage
C Booth et al.
CELL PROLIFERATION (2004)
The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients
PF Yumuk et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2004)
Glucagon-like peptide-2 and common therapeutics in a murine model of ulcerative colitis
MC L'Heureux et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Glucagon-like peptide-2-enhanced barrier function reduces pathophysiology in a model of food allergy
HL Cameron et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2003)
Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer
K Mori et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2003)
Glucagon-like peptides: Regulators of cell proliferation, differentiation, and apoptosis
DJ Drucker
MOLECULAR ENDOCRINOLOGY (2003)
Prevention of chemotherapy and radiation toxicity with glutamine
DMF Savarese et al.
CANCER TREATMENT REVIEWS (2003)
Glucagon-like peptide-2 receptor activation engages bad and glycogen synthase kinase-3 in a protein kinase A-dependent manner and prevents apoptosis following inhibition of phosphatidylinositol 3-kinase
B Yusta et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer
RJ Gibson et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2002)
Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma
ML Delloukina et al.
CANCER (2002)
Control of irinotecan-induced diarrhea by octreotide after loperamide failure
V Barbounis et al.
SUPPORTIVE CARE IN CANCER (2001)
Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in Caco-2 cells - Potential role in carcinogen bioinactiviation
A Galijatovic et al.
PHARMACEUTICAL RESEARCH (2001)
The glucagon-like peptide-2 receptor mediates direct inhibition of cellular apoptosis via a cAMP-dependent protein kinase-independent pathway
B Yusta et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Structural determinants for activity of glucagon-like peptide-2
MP DaCambra et al.
BIOCHEMISTRY (2000)
Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse
MA Benjamin et al.
GUT (2000)
Restoration of tight junction structure and barrier function by down-regulation of the mitogen-activated protein kinase pathway in Ras-transformed Madin-Darby canine kidney cells
YH Chen et al.
MOLECULAR BIOLOGY OF THE CELL (2000)
Hormonal therapy for short bowel syndrome
DL Sigalet et al.
JOURNAL OF PEDIATRIC SURGERY (2000)
Enteroendocrine localization of GLP-2 receptor expression in humans and rodents
B Yusta et al.
GASTROENTEROLOGY (2000)
Structure, measurement, and secretion of human glucagon-like peptide-2
B Hartmann et al.
PEPTIDES (2000)
分享论文
